Loading
A phase 2 trial of Pembrolizumab, Cisplatin, Gemcitabine, Pemetrexed, Sacituzumab tirumotecan and Dexamethasone in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) is a phase 2 interventional study registered as NCT06788912 by Merck Sharp & Dohme LLC, with 60 participants planned, started 2025-03-20 and due to reach its primary completion in 2032-02-06. Interventions recorded: Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine, Pemetrexed, Sacituzumab tirumotecan and H1 receptor antagonist.
Shares Sacituzumab tirumotecan, Dexamethasone, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pemetrexed, Merck & Co. (MSD), Gemcitabine, Cisplatin and the tag pipeline.